Summary:
- The FDA is soliciting public feedback to refine the regulatory framework for the development of botanical drug products, which are complex mixtures derived from plants, algae, or macroscopic fungi.
- The initiative aims to provide clearer guidance for manufacturers, ensuring that these products meet rigorous standards for safety, efficacy, and quality control comparable to conventional pharmaceutical drugs.
- This effort highlights the intersection of traditional pharmacological knowledge and modern evidence-based medicine, seeking to address the unique challenges of standardizing chemically complex natural substances.